In collaboration with the laboratory of Prof. David Shapiro (UIUC Biochemistry) we have discovered a family of potent and selective anticancer agents, headlined by the compound ErSO.  ErSO and its derivatives induce quantitative tumor regression in certain xenograft models and have tremendous translational potential.

Related Publications

Plasma Membrane Channel TRPM4 Mediates Immunogenic Therapy-Induced Necrosis
Ghosh S, Yang R, Duraki D, Zhu J, Kim JE, Jabeen M, Mao C, Dai X, Livezey MR, Boudreau MW, Park BH, Nelson ER, Hergenrother PJ, Shapiro DJ
Cancer Res. 2023, 83, 3115-3130.

Evolution of 3-(4-hydroxyphenyl)indoline-2-one as a scaffold for potent and selective anticancer activity
Boudreau, M.W. and Hergenrother, P.J.
RSC Med. Chem. 2022, 13, 711-725

Activators of the anticipatory unfolded protein response with enhanced selectivity for estrogen receptor positive breast cancer
Boudreau, M.W.; Mulligan, M.P.; Shapiro, D.J.; Fan, T.M.; Hergenrother, P.J.
J. Med. Chem. 2022, 65, 3894-3912

A small molecule activator of the unfolded protein response eradicates human breast tumors in mice
Boudreau, MW; Duraki, D; Wang, L.; Mao, C.; Kim, J.E.; Tang, B.; Fanning, S.W.; Kiefer, J.; Tarasow, T.M.; Bruckheimer, E.M.; Moreno, R.; Mousses, S.; Greene, G.L.; Roy, E.J.; Park, B.H.; Fan, T.M.; Nelson, E.R.; Hergenrother, P.J.; Shapiro, D.J.
Science Transl. Med. 2021, 13, eabf1383